#7 - Lantheus Holdings (NASDAQ:LNTH)
Lantheus Holdings Inc. (NASDAQ: LNTH) is a medical devices company that specializes in three areas: radiopharmaceutical oncology, precision diagnostics (especially in cardiology), and strategic partnerships to advance precision medicine.
The company’s stock is up $44 in 2024, but analysts believe it may just be getting started. As of November 2024, they give LNTH stock a Moderate Buy rating with a $122.50 price target, representing a 35% upside for the stock.
That may be due, in part, to the company’s November 2024 announcement of a $250 million share buyback program that will be in place for one year. And lest you think that the company is issuing a buyback program to hide financial weakness, Lantheus is delivering YoY growth in revenue and earnings.
About Lantheus
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.
Read More - Current Price
- $92.79
- Consensus Rating
- Buy
- Ratings Breakdown
- 7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $131.86 (42.1% Upside)
According to Wedbush analyst Dan Ives, investors should prepare for “a tidal wave of tech M&A and overall deal activity" in a Trump administration. And if the M&A boom occurs, it won't only happen in tech. Investors should also look at consumer staples, healthcare, and any company that has a healthy cash balance to put towards growth through acquisition strategy.
There's no guarantee that any of these stocks will be part of merger activity in 2025. If the Federal Reserve pauses their rate cut campaign, it may make companies more hesitant to make deals. However, each of the companies in this presentation fit a pattern of having positive cash flow, sales growth, and little to no debt.
You can use the MarketBeat Stock Screener to find mid-cap stocks that fit those criteria. The Russell 2000 stock list on MarketBeat is another place to find attractive mid-cap stocks.
More Investing Slideshows:
